ESC 365 - Empagliflozin prevention of heart failure development in diabetes is associated with an improvement in cardiac energy producition

ESC Premium Access

Empagliflozin prevention of heart failure development in diabetes is associated with an improvement in cardiac energy producition

Session: Targeting reverse remodelling in heart failure

Topic: Pharmacotherapy

Speaker: Professor S. Verma (Toronto, CA)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)

31 presentations

2 followers

6 more presentations in this session

Feasibility and efficacy of early donepezil with or without metoprolol in reperfused myocardial infarction rats

Speaker: Doctor M. Li (Osaka, JP)

The best of two worlds: Vascular protection and decongestion without RAAS stimulation mediated by a novel dual acting V1a/V2 vasopressin receptor antagonist

Speaker: Doctor P. Kolkhof (Wuppertal, DE)

Cardioprotective effects of a novel designer C-type natriuretic peptide-based therapeutic, C53 , for the prevention of post-myocardial infarction heart failure

Speaker: Mr Y. Chen (Rochester, US)

Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat

Speaker: Doctor H. Yip (Kaohsiung, TW)

Empagliflozin improves left ventricular diastolic function in db/db mice without altering cardiac expression of enzymes relevant for ketone body or branched chain amino acid catabolism.

Speaker: Miss J. Moellmann (Aachen, DE)

Access the full session

Targeting reverse remodelling in heart failure

Speakers: Professor S. Verma, Doctor M. Li, Doctor P. Kolkhof, Mr Y. Chen, Doctor H. Yip...

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources